Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EP1013 is a broad-spectrum selective inhibitor of Caspase used in the study of type 1 diabetes.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 759.00 | |
50 mg | 8-10 weeks | $ 986.00 | |
100 mg | 8-10 weeks | $ 1,590.00 |
Description | EP1013 is a broad-spectrum selective inhibitor of Caspase used in the study of type 1 diabetes. |
In vivo | EP1013 therapy significantly improves the functionality and longevity of syngeneic islet grafts by enhancing the islet mass's performance. Administering EP1013 at dosages of 1, 3, and 10 mg/kg results in noticeable improvements in the function of marginal islet mass. Despite two cases of primary islet graft nonfunction in the 10 mg/kg EP1013 treatment group, the overall rate of diabetes reversal among this group does not significantly differ from those treated with 3 mg/kg EP1013, 1 mg/kg EP1013, or 10 mg/kg zVAD. |
Synonyms | F1013 |
Molecular Weight | 382.38 |
Formula | C18H23FN2O6 |
CAS No. | 223568-55-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (156.91 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EP1013 223568-55-6 Apoptosis Proteases/Proteasome Caspase F1013 F-1013 EP 1013 F 1013 EP-1013 inhibitor inhibit